30 closest matches · ranked by relevance
Acute Kidney Injury · Nephrotoxicity
Primary: Number of Patients With Nephrotoxic Medication Associated AKI Detected by Urinary NGAL — 3; 6; 24; 80 Participants
Renal Insufficiency
Primary: Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis…
Coronary Artery Stenosis
Primary: Impact on the Trajectory of Serum and Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) Following Administration — -27.76; -11.11; -11.84; -8.23 ng/mL
Osteosarcoma · Nephrotoxicity · Ototoxicity
Primary: Change in Urinary Biomarkers of Acute Kidney Injury (AKI) Between Pre-Treatment (Baseline), After CISplatin (C) Treatments, and After HDTMX Treatments — 1.7; 1.7; 2.1…
Total Fluid Volume Increased
Primary: Concentration of NGAL in Urine on 5 Time Point — 5.6; 4.9; 5.2; 5.1 ng/ml
Radiocontrast-induced Nephropathy
Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min
Intensive Monitoring of Renal Function · Acute Kidney Injury
Primary: Detection of Acute Kidney Injury (AKI) — 1.22; 1.22; 1.11; 1.11 Odds Ratio
CNI Side Effects
Primary: Phase I: The Minimization of Negative Side Effects - Patient Survival — 99; 98 percentage of participants
Acute Kidney Injury
Primary: Percentage of Patients With Progression of AKI OR Dialysis OR Death — 639; 585 Participants
Radiocontrast Nephropathy
Primary: Number of Participants With Contrast-induced Nephropathy — 14; 12 Participants — p=>0.5
Contrast Induced Nephropathy
Primary: Change in GFR — 1.8; -4.1 mL/min
Gram-Negative Bacterial Infections · Sepsis
Primary: Number of Participants Not Requiring Renal Replacement Therapy (RRT) — 3; 1 participants
Carcinoma, Renal Cell · Kidney Disease · Kidney Cancer
Primary: Time-to-progression (TTP) — 5.3 months
Acute Kidney Failure
Primary: Progression to Stage 3 AKI — 23 Participants
Chronic Kidney Disease
Primary: Number of Participants With Contrast-induced Acute Kidney Injury — 146; 146 participants
Acute Kidney Injury
Primary: Incidence of Anticoagulant-related Nephropathy in the Cohort — 0 Percentage of participants
Lupus Nephritis
Primary: Complete and Partial Response Rate — 55 Percentage of participants
Renal Insufficiency
Primary: Area Under the Curve From Time Zero to 48 Hours[AUC (0 - 48)] — 1294; 1399; 2024; 2860 Nanogram*hour/milliliter (ng*h/mL)
Failing Renal Allograft
Primary: Number of Participants With Donor-specific Antibody Formation — 3; 4 Participants
Kidney Transplantation · Chronic Kidney Failure
Primary: Percent of Participants Surviving With a Functioning Graft by Month 12 — 92.8; 96.5; 95.4 percentage of participants
Transplant, Liver
Primary: Glomerular Filtration Rate (GFR) — 69; 64 ml/min/1.73m^2 — p=0.0001
Kidney Failure, Acute
Primary: Adverse Drug Events or Potential Adverse Drug Events — 99; 104 Patient-Medication Pairs
Renal Failure
Primary: Measure Neutrophils to Measure Kidney Injury — 5.453; 5.630; 4.508; 4.546 log2 expression
Acute Kidney Injury Due to Sepsis
Primary: Maximum Serum Concentration (Cmax) of TIN816 — 40.8 ug/mL
Renal Insufficiency
Primary: Number of Patients With Moderate to Severe Renal Impairment Who Develop Nephrogenic Systemic Fibrosis (NSF) After Administration of Dotarem — 0 Participants
Kidney Failure, Chronic · Kidney Failure, Acute · Heart Failure
Primary: Number of Participants With Acute Kidney Injury During the First 48 Hours After Contrast Administration — 5; 4 Participants
Sepsis · AKI · Neurotoxicity
Primary: Acute Kidney Injury (AKI) Ordinal Scale — 910; 952; 86; 100 Participants
Acute Kidney Injury
Primary: Acute Kidney Injury — 110; 190; 122; 88 Participants
IgA Nephropathy
Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants
Chronic Kidney Disease
Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants